Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Anti-Cancer Therapies, Pigmentary Changes Linked

J Am Acad Dermatol; ePub 2017 Sep 14; Dai, Belum, et al

There is a significant risk of development of pigmentary changes during treatment with targeted anti-cancer therapies, according to a recent study. Therefore, appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life. A comprehensive search was conducted to identify studies reporting targeted therapy–induced pigmentary changes. The incidence and relative risk were calculated and case reports and series were reviewed to understand clinical characteristics. A total of 8,052 patients from 36 clinical trials were included. Researchers found:

  • The calculated overall incidences of targeted cancer therapy-induced all-grade pigmentary changes in the skin and hair were 17.7% and 21.5%, respectively.
  • The relative risk of all-grade pigmentary changes of skin and hair were 93.7 and 20.1.
  • Across 53 case reports/series (n=75 patients), epidermal growth factor receptor and breakpoint cluster region-abelson inhibitors were the most common offending agents.
Citation:

Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. [Published online ahead of print September 14, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.06.044.

This Week's Must Reads

Anti-Cancer Therapies, Pigmentary Changes Linked, J Am Acad Dermatol; ePub 2017 Sep 14; Dai, Belum, et al

Patient-Reported Global Severity of Adult AD, Allergy; ePub 2017 Sep 14; Vakharia, Chopra, et al

Quantitative ABCD Skin Lesion Parameters Assessed, Dermatol Online J; 2017 Aug; Glazer, Farberg, et al

Most "Dog-Ears" Show Complete Resolution, Dermatol Surg; ePub 2017 Sep 19; Jennings, et al

Chemical Peels: Special Considerations for Men, Dermatol Surg; ePub 2017 Sep 4; Reserva, et al

Must Reads in Pigmentation Disorders

Anti-Cancer Therapies, Pigmentary Changes Linked, J Am Acad Dermatol; ePub 2017 Sep 14; Dai, Belum, et al

Morphologic CALM Features Help Determine Treatment, JAMA Dermatol; ePub 2017 Aug 30; Belkin, et al

MKTP Procedure Satisfactory for Leukoderma Treatment, J Am Acad Dermatol; ePub 2017 May 11; Silpa-Archa, et al

Hyperpigmentation Patients: Less Sunscreen Usage, J Am Acad Dermatol; ePub 2017 Feb 15; Maymone, et al

Risk Factors for Vitiligo Examined in Women, J Invest Dermatol; ePub 2017 Feb 14; Dunlap, et al